Role of flow cytometry in diagnostics of myelodysplastic syndromes-beyond the WHO 2008 classification

Seminars in Diagnostic Pathology

Volumn 28, Issue 4, 2011, Pages 273-282

  Porwit, Anna ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Flow cytometry; Immunophenotyping; Myelodysplastic syndromes

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTIGEN; B7 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD235A ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; LEUKOSIALIN; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BASOPHILIC ERYTHROBLAST; BLAST CELL; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL POPULATION; CELL STRUCTURE; CONSENSUS; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC VALUE; ERYTHROBLAST; ERYTHROPOIESIS; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LYMPHOID CELL; MONOCYTE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NEUTROPHIL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REFRACTORY ANEMIA; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

BONE MARROW CELLS; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES; WORLD HEALTH ORGANIZATION;

EID: 82455219218     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.06.003     Document Type: Article

References (89)

1. Jaffe E.S., Harris N.L., Stein H., et al. World Health Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC 2001.
2. Stetler-Stevenson M., Arthur D.C., Jabbour N., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001, 98:979-987.
3. Kussick S.J., Fromm J.R., Rossini A., et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005, 124:170-181.
4. Maynadié M., Picard F., Husson B., et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002, 100:2349-2356.
5. Della Porta M.G., Malcovati L., Invernizzi R., et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006, 20:549-555.
6. Ogata K., Nakamura K., Yokose N., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002, 100:3887-3896.
7. Wells D.A., Benesch M., Loken M.R., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102:394-403.
8. Benesch M., Deeg H.J., Wells D., et al. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology 2004, 9:171-177.
9. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphatic Tissues. Lyon, IARC 2008.
10. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
11. Valent P., Hofmann W.K., Büsche G., et al. Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. Ann Hematol 2009, 88:607-611.
12. van de Loosdrecht A.A., Alhan C., Béné M.C., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94:1124-1134.
13. Watkins N.A., Gusnanto A., de Bono B., et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 2009, 113:e1-e9.
14. Terstappen L.W., Levin J. Bone marrow cell differential counts obtained by multidimensional flow cytometry. Blood Cells 1992, 18:311-330.
15. Terstappen L.W., Safford M., Loken M.R. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 1990, 4:657-663.
16. Terstappen L.W., Johnsen S., Segers-Nolten I.M., et al. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990, 76:1739-1747.
17. Terstappen L.W., Loken M.R. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990, 2:229-240.
18. Porwit-MacDonald A., Björklund E., Lucio P., et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000, 14:816-825.
19. Lúcio P., Parreira A., van den Beemd M.W., et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999, 13:419-427.
20. Matarraz S., Lopez A., Barrena S., et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008, 22:1175-1183.
21. Macedo A., Orfao A., Ciudad J., et al. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995, 9:1896-1901.
22. Kern W., Danhauser-Riedl S., Ratei R., et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003, 88:646-653.
23. van Lochem E.G., van der Velden V.H., Wind H.K., et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 2004, 60:1-13.
24. Olaru D., Campos L., Flandrin P., et al. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom 2008, 74:17-24.
25. + cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients. Int J Hematol 2009, 90:292-302.
26. Wood B. Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol 2004, 75:559-576.
27. Arnoulet C., Béné M.C., Durrieu F., et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom 2010, 78:4-10.
28. Stelzer G.T., Shults K.E., Loken M.R. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993, 677:265-280.
29. Borowitz M.J., Guenther K.L., Shults K.E., et al. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993, 100:534-540.
30. Elghetany M.T., Ge Y., Patel J., et al. Flow cytometric study of neutrophilic granulopoiesis in normal bone marrow using an expanded panel of antibodies: correlation with morphologic assessments. J Clin Lab Anal 2004, 18:36-41.
31. Edvardsson L., Dykes J., Olsson M.L., et al. Clonogenicity, gene expression and phenotype during neutrophil versus erythroid differentiation of cytokine-stimulated CD34+ human marrow cells in vitro. Br J Haematol 2004, 127:451-463.
32. Loken M.R., Shah V.O., Dattilio K.L., et al. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 1987, 69:255-263.
33. Mirabelli P., Di Noto R., Lo Pardo C., et al. Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: implication for erythroid differentiation studies. BMC Physiol 2008, 8:13.
34. Lacombe F., Durrieu F., Briais A., et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997, 11:1878-1886.
35. + cells and CFU-GM and are useful predictor of haemopoietic recovery after autologous BPC transplantation collections. Bone Marrow Transplant 1998, 21:869-872.
36. Kern W., Haferlach C., Schnittger S., et al. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010, 116:4549-4563.
37. Xu F., Li X., Wu L., et al. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol 2010, 149:587-597.
38. Cutler J.A., Wells D.A., van de Loosdrecht A.A., et al. Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. Cytom B Clin Cytom 2010, epub ahead of print 23 December 2010.
39. Harrington A., Olteanu H., Kroft S. The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. Am J Clin Pathol 2010, 134:749-761.
40. Loken M.R., Chu S.C., Fritschle W., et al. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 2008, 76B:27-36.
41. Yahata T., Muguruma Y., Yumino S., et al. Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis. Stem Cells 2008, 26:3228-3236.
42. + cells as a diagnostic test in myelodysplastic syndromes. Haematologica 2009, 94:1160-1163.
43. +/CD38dim in myelodysplasia. Cytom B Clin Cytom 2006, 70:63-70.
44. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
45. - bone marrow cells in myelodysplastic syndromes. Cytometry A 2010, 77:840-848.
46. Truong F., Smith B.R., Stachurski D., et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009, 33:1039-1046.
47. Cherian S., Moore J., Bantly A., et al. Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol 2005, 79:243-245.
48. Cherian S., Moore J., Bantly A., et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005, 64:9-17.
49. Lacronique-Gazaille C., Chaury M.P., Le Guyader A., et al. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 2007, 92:859-860.
50. TM. Int J Lab Hematol 2010, 32:e237-e243.
51. Xu Y., McKenna R.W., Karandikar N.J., et al. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005, 124:799-806.
52. Maciejewski J.P., Rivera C., Kook H., et al. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol 2001, 115:1015-1022.
53. Kyriakou D., Liapi D., Kyriakou E., et al. Aberrant expression of the major sialoglycoprotein (CD43) on the monocytes of patients with myelodysplastic syndromes. Ann Hematol 2000, 79:198-205.
54. Meers S., Kasran A., Boon L., et al. Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells. Leukemia 2007, 21:2411-2419.
55. Alexandrakis M., Coulocheri S., Xylouri I., et al. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes. Haematologia (Budap) 1998, 29:13-24.
56. Malcovati L., Della Porta M.G., Lunghi M., et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005, 19:776-783.
57. + cells in low-grade myelodysplastic syndromes. Blood 2006, 108:1037-1044.
58. Veltroni M., Sainati L., Zecca M., et al. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. Pediatr Blood Cancer 2009, 52:357-363.
59. Ribeiro E., Matarraz Sudón S., de Santiago M., et al. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leuk Res 2006, 30:9-16.
60. Reis S.C., Traina F., Metze K., et al. Variation of bone marrow CD34+ cell subsets in myelodysplastic syndromes according to WHO types. Neoplasma 2009, 56:435-440.
61. Ogata K., Della Porta M.G., Malcovati L., et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009, 94:1066-1074.
62. Sternberg A., Killick S., Littlewood T., et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005, 106:2982-2991.
63. Béné M.C., Nebe T., Bettelheim P., et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011, 25:567-574.
64. Fozza C., Contini S., Galleu A., et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009, 37:947-955.
65. Alfinito F., Sica M., Luciano L., et al. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 2010, 148:90-98.
66. + T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 2009, 23:1288-1296.
67. Kordasti S.Y., Afzali B., Lim Z., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145:64-72.
68. +CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23:510-518.
69. Bacher U., Haferlach T., Kern W., et al. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer 2009, 115:4524-4532.
70. Otawa M., Kawanishi Y., Iwase O., et al. Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. Leuk Res 2000, 24:359-366.
71. Kasahara S., Hara T., Itoh H., et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. Br J Haematol 2002, 118:181-188.
72. Valent P., Horny H.P. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009, 39:548-553.
73. van de Loosdrecht A.A., Westers T.M., Westra A.H., et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008, 111:1067-1077.
74. Pirruccello S.J., Young K.H., Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 2006, 125:884-894.
75. Scott B.L., Wells D.A., Loken M.R., et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008, 112:2681-2686.
76. Arroyo J.L., Fernández M.E., Hernández J.M., et al. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 2004, 5:227-233.
77. Chu S.C., Wang T.F., Li C.C., et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011, 35:868-873.
78. Westers T.M., Alhan C., Chamuleau M.E., et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010, 115:1779-1784.
79. Cesana C., Klersy C., Brando B., et al. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res 2008, 32:1715-1723.
80. Hellström-Lindberg E., Ahlgren T., Beguin Y., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998, 92:68-75.
81. Ogata K., Yoshida Y. Clinical implications of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma 2005, 46:1269-1274.
82. Miesner M., Haferlach C., Bacher U., et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood 2010, 116:2742-2751.
83. Hasserjian R.P., Zuo Z., Garcia C., et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood 2010, 115:1985-1992.
84. Kasyan A., Medeiros L.J., Zuo Z., et al. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol 2010, 23:1113-1126.
85. Stachurski D., Smith B.R., Pozdnyakova O., et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008, 32:215-224.
86. Matarraz S., López A., Barrena S., et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom 2010, 78:154-168.
87. Xu D., Schultz C., Akker Y., et al. Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. Am J Hematol 2003, 74:9-16.
88. Moon H.W., Huh J.W., Lee M., et al. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes. Korean J Lab Med 2010, 30:97-104.
89. Lorand-Metze I., Ribeiro E., Lima C.S., et al. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007, 31:147-155.